Viral Vector Collaboration and Licensing Deals 2016-2023
Viral Vector Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2016 to 2023
Viral Vector Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the viral vector deals entered into by the worlds leading biopharma companies.
Fully revised and updated, the report provides details of viral vector deals from 2016 to 2023.
The report provides a detailed understanding and analysis of how and why companies enter viral vector deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
The report includes collaboration, development, research and licensing deals.
This report contains a comprehensive listing of 377 viral vector deals announced since 2016 including financial terms where available including links to online deal records of actual viral vector partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of viral vector dealmaking.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in viral vector dealmaking since 2016.
Chapter 3 provides an overview of the leading viral vector deals since 2016. Deals are listed by headline value.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in viral vector dealmaking with a brief summary followed by a comprehensive listing of viral vector deals, as well as contract documents available in the public domain.
Chapter 5 provides a comprehensive and detailed review of viral vector deals signed and announced since Jan 2016, where a contract document is available in the public domain.
Chapter 6 provides a comprehensive and detailed review of viral vector partnering deals signed and announced since Jan 2016. The chapter is organized by specific viral vector technology type in focus.
The report also includes numerous table and figures that illustrate the trends and activities in viral vector deal making since 2016.
In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Key benefits
Viral Vector Collaboration and Licensing Deals provides the reader with the following key benefits:
• Understand deal trends since 2016
• Browse viral vector collaboration and licensing deals
• Benchmark analysis – identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time
Report scope
Viral Vector Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of viral vector trends and structure of deals entered into by leading biopharma companies worldwide.
Viral Vector Collaboration and Licensing Deals includes:
• Trends in viral vector dealmaking in the biopharma industry
• Directory of viral vector deal records covering pharmaceutical and biotechnology
• The leading viral vector deals by value
• Most active viral vector licensing dealmakers
Viral Vector Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.
Analyzing contract agreements allows due diligence of:
• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?
Viral Vector Collaboration and Licensing Deals provides the reader with the following key benefits:
• Understand deal trends since 2016
• Browse viral vector collaboration and licensing deals
• Benchmark analysis – identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in viral vector dealmaking
2.1. Introduction
2.2. Viral vector deals over the years
2.3. Most active viral vector dealmakers
2.4. Viral vector deals by deal type
2.5. Viral vector deals by therapy area
2.6. Viral vector deals by industry sector
2.7. Deal terms for viral vector deals
2.7.1 Viral vector deals headline values
2.7.2 Viral vector deal upfront payments
2.7.3 Viral vector deal milestone payments
2.7.4 Viral vector royalty rates
Chapter 3 – Leading viral vector deals
3.1. Introduction
3.2. Top viral vector deals by value
Chapter 4 – Most active viral vector dealmakers
4.1. Introduction
4.2. Most active viral vector dealmakers
4.3. Most active viral vector deals company profiles
Chapter 5 – Viral vector contracts dealmaking directory
5.1. Introduction
5.2. Viral vector contracts dealmaking directory
Chapter 6 – Viral vector dealmaking by technology type
Deal directory
Deal directory – Viral vector deals by company A-Z
Deal directory – Viral vector deals by deal type
Deal directory – Viral vector deals by therapy area
Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from Current Partnering
Table of figures
Figure 1: Viral vector deals since 2016
Figure 2: Active viral vector dealmaking activity – 2016 - 2023
Figure 3: Viral vector deals by deal type since 2016
Figure 4: Viral vector deals by therapy area since 2016
Figure 5: Viral vector deals by industry sector since 2016
Figure 6: Viral vector deals with a headline value
Figure 7: Viral vector deals with an upfront value
Figure 8: Viral vector deals with a milestone value
Figure 9: Viral vector deals with a royalty rate value
Figure 10: Top viral vector deals by value since 2016
Figure 11: Most active viral vector dealmakers 2016 - 2023
Figure 12: Viral vector deals by technology type since 2016
Pricing options
- $3,995: single-user (encrypted file - one user/device)
- $5,995: multi-user (encrypted file - up to 5 users/devices)
- $9,995: company (unencrypted file)
Single and Multi-user license files are encrypted PDF documents. Details of how to access using Javelin3 PDF Reader will be provided at report delivery.
Company license files are not encrypted and can be accessed using a PDF Reader.
A full explanation of license type definitions can be found here.
Our guarantee
Price promise
We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.
Delivery Deadline
We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)
Latest report
If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.
Serious Security
We take your data and security seriously. See our privacy policy for details of how we manage your data.
All card payments are processed by Evalon.
Sales Support
If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.
- Total Trust
Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.
2A, 2seventy bio, 3T Biosciences, 4D Molecular Therapeutics, AavantiBio, AAVnerGene, Abbvie, Abeona Therapeutics, ABL Bio, Abzena, Academy of Military Medical Sciences (China), Accelerator for Technological Research in Genomic Therapies, Adaptive Phage Therapeutics, Adverum Biotechnologies, Aevitas Therapeutics, Affini-T Therapeutics, Affinia Therapeutics, AGC Biologics, Akouos, Alaunos Therapeutics, Albumedix, Alcyone Lifesciences, Aldevron, Alpha Teknova, Altimmune, American Gene Technologies, Amicus Therapeutics, AmpliPhi Biosciences, Applied DNA Sciences, Applied Genetic Technologies, Aptuit, Armata Pharmaceuticals, Aruvant Sciences, ASC Therapeutics, Asimov, Asklepios Biopharmaceutical, Astellas Pharma, Astellas Pharma US, AstraZeneca, Athebio, Athenex, Auburn University, Audentes Therapeutics, Autodesk, Avance Biosciences, Avantor, Avista Therapeutics, Avrobio, Axovant Gene Therapies, Bayer, Baylor College, Beam Therapeutics, Benitec Biopharma, Berkeley Lights, Bespoke Gene Therapy Consortium, Bharat Biotech, Bicycle Therapeutics, BIOASTER, Biogen, Bioharmony Therapeutics, BioInvent, BioMarin Pharmaceutical, Biomedical Advanced Research and Development Authority, BiomX, Bionic Sight, BionX Medical Technologies, Biophage Pharma, Biotechnology and Biological Sciences Research Council (BBSRC), Biotheus, Bioverativ, Bluebird Bio, Boehringer Ingelheim, Brammer Bio, BriaCell Therapeutics, BridgeBio Pharma, Bristol-Myers Squibb, Broad Institute, Cabaletta Bio, Calidi Biotherapeutics, California Institute for Regenerative Medicine, California Institute of Technology, Calimmune, CANbridge Pharmaceuticals, Capsida Biotherapeutics, Capsigen, CARB-X, Carisma Therapeutics, Casebia Therapeutics, Case Western Reserve University, Catalent, Cell and Gene Therapy Catapult, Cellares, Cellevolve Bio, Cell Mogrify, Cell Point, Center for Breakthrough Medicines, Center for Genomic Regulation, Cevec Pharmaceuticals, Charles River Laboratories, Children's Medical Research Institute, City of Hope, Clearside Biomedical, Cleveland Clinic, Coalition for Epidemic Preparedness Innovations, Coave Therapeutics, Cobra Biologics, Cognate BioServices, Columbia University, ContraFect, Cornell University, CPI International, CRISPR Therapeutics, CSL Behring, Cure Genetics, Curigin, Cyagen Biosciences, Cyprium Therapeutics, Cystic Fibrosis Foundation, Cytoo, Cytovance Biologics, Daiichi Sankyo, Dartmouth College, DCM, Decibel Therapeutics, Defense Health Agency (US), Denali Therapeutics, Department of Defense, Desktop Genetics, Dimension Therapeutics, DiNAQOR, Dr. Reddy's Laboratories, Duke University, Dyno Therapeutics, Editas Medicine, Eikonoklastes Therapeutics, ElevateBio, Eligo Bioscience, Emory University, EnBiotix, Enesi Pharma, Enlivex, Ensoma, ERS Genomics, Eunice Kennedy Shriver Institute of Child Health and Human Development, Eureka Therapeutics, Evox Therapeutics, Exothera, Expression Therapeutics, F1 Oncology, Federal Ministry of Education and Research (BMBF), Felix Biotechnology, Ferring Pharmaceuticals, Forcefield Therapeutics, Forge Biologics, Fortress Biotech, Forty Seven, Foundation Fighting Blindness, Foundation to Fight H-ABC, Freeline Therapeutics, Fujifilm Diosynth Biotechnologies, G-Con, GE Healthcare, Gen9, GeneCraft, Genelux, Genenta Science, Generation Bio, Generation Biotech, Genethon, GenKOre, Genosera, Genovis, Genprex, Gensaic, GenScript Biotech, GenScript ProBio, GentiBio, Genzyme, GeoVax, Gilead Sciences, Ginkgo BioWorks, GlycoBac, Great Ormond Street Hospital (GOSH), Gritstone Bio, GSK, Gyroscope Therapeutics, Hadassah Medical Center, HaemaLogiX, Hansa Biopharma, Hebrew University of Jerusalem, Homology Medicines, Horizon Discovery, Hunterian Medicine, Iaso Therapeutics, Icahn School of Medicine at Mount Sinai, Ikarovec, ImmunityBio, ImmVira, Imperial Innovations, Imugene, Indee Labs, InnoBation, Innovate UK, InProTher, Inscripta, Institute of Child Health, Institute of Neurodegenerative Diseases, Intellia Therapeutics, Interbiome, International AIDS Vaccine Initiative, Intralytix, iNtRON Biotechnology, Iveric Bio, iVexSol, Janssen Biotech, Janssen Pharmaceuticals, Jasper Therapeutics, Jenner Institute, Johns Hopkins University, Johnson & Johnson Innovation, JSR, Juno Therapeutics, KaliVir Immunotherapeutics, Kiromic Biopharma, Kissei Pharmaceutical, Kriya Therapeutics, Kyverna Therapeutics, Laboratory Corporation of America, Lacerta Therapeutics, Leiden University, Leidos, Lesaffre, Leukocare, LEXEO Therapeutics, Locus Biosciences, LogicBio Therapeutics, Lonza, Lysogene, Magenta Therapeutics, Massachusetts Eye and Ear Infirmary, Massachusetts General Hospital, Matica Biotechnology, Max-Delbruck Center for Molecular Medicine, Mayo Clinic, Mayo Clinical Ventures, McMaster University, Medac, MediGene, MedImmune, MeiraGTx, Microsoft, MilliporeSigma, Mirum Pharmaceuticals, Mission Bio, MolMed, Morgenesis, Mosaic ImmunoEngineering, Mount Sinai Health System, MSD, Muscular Dystrophy Association, Mustang Bio, Myrtelle, NantOmics, National Cancer Institute, National Institute of Allergy and Infectious Diseases, National Institutes of Health, National Research Council Canada, National Resilience, National Science Foundation, Nationwide Children’s Hospital, Navy Medical Research Centre, NEC, NecstGen, Neuracle Genetics, Neurimmune Therapeutics, Neurochase, Neurocrine Biosciences, Neurophth Therapeutics, Newsoara Biopharma, Noga Therapeutics, Northwestern University, Novartis, Novasep, NYU Langone Medical Center, Oculogenex, Ophthotech, Opus Genetics, Orchard Therapeutics, Oregon Health Sciences University, Oregon National Primate Research Center, Otsuka, Ovid Therapeutics, Oxford BioMedica, Oxford Genetics, Oxgene, Oyster Point Pharma, Pall Corporation, Papyrus Therapeutics, Paragon Bioservices, Passage Bio, Passport Food Safety Solutions, PaxVax, Perelman School of Medicine, PersonGen BioTherapeutics, Peter MacCallum Cancer Institute, Pfizer, Phagelux, Pherecydes Pharma, PlasmidFactory, Plasticell, Polyplus Transfection, Precigen, Precision Virologics, Pregene Biopharma, Prevail Therapeutics, ProteoNic, Provecs Medical, PsiOxus Therapeutics, rAAVen Therapeutics, Ray Therapeutics, Regeneron Pharmaceuticals, Regenxbio, ReiThera, Renova Therapeutics, RenovoRx, Rentschler Biotechnologie, Rescue Hearing, Resilience, Reyon Pharmaceuticals, Roche, Rocket Pharmaceuticals, Rokote Laboratories, Russian Direct Investment Fund, Rznomics, Saint Louis University, Sangamo Therapeutics, Sanofi, Santen Pharmaceutical, Santhera Pharmaceuticals, Sarepta Therapeutics, Sartorius, Sartorius Stedim Biotech, SCTbio, Seattle Children's Therapeutics, Selecta Biosciences, Sensei Biotherapeutics, Sensorion, Shape Therapeutics, Sirion Biotech, Skyline Therapeutics, Solid Biosciences, Solve GNE, SparingVision, Spark Therapeutics, SpliceBio, SQZ Biotech, St. Jude Children's Research Hospital, Stanford University, St Jude Medical, StrideBio, Summit Biosciences, SunTerra Biotechnology, Symbiosis, Synpromics, Takeda Pharmaceutical, Tamid Bio, Targovax, Taysha Gene Therapies, Terumo Blood and Cell Technologies, Tetherex Pharmaceuticals, Texcell, TFF Pharmaceuticals, The Native Antigen Company, Theravectys, Thermo Fisher Scientific, Tianjin CanSino Biotechnology, TILT Biotherapeutics, Touchlight, Transgene, Trieza Therapeutics, Turnstone Biologics, Twist Bioscience, UCB, UK Cystic Fibrosis Gene Therapy Consortium, Ultragenyx Pharmaceuticals, UniQure, Univercells, University of Basel, University of California Berkeley, University of California Los Angeles, University of California San Francisco, University of Chicago, University of Edinburgh, University of Florida, University of Florida Research Foundation, University of Helsinki, University of Kansas, University of Leeds, University of Manchester, University of Massachusetts, University of Massachusetts Medical School, University of Miami, University of Minnesota, University of North Carolina, University of Oxford, University of Pennsylvania, University of Pennsylvania School of Veterinary Medicine, University of Pittsburgh, University of Texas Southwestern Medical Center, University of Western Sydney, US Army, Vaccitech, Valo Therapeutics, Vaxalto Biotherapeutics, Vectalys, VectorBuilder, VectorY Therapeutics, Verismo Therapeutics, Vertex Pharmaceuticals, VIB, Vifor-Fresenius Medical Care Renal Pharma, ViGeneron, Viralgen, Vir Biotechnology, Virginia Commonwealth University, Virica Biotech, VIVEbiotech, Vivet Therapeutics, Voyager Therapeutics, Vyriad, Wageningen University, Walter Reed Army Institute of Research, Washington University in St Louis, Weizmann Institute, Westmead Institute for Medical Research, WhiteLab Genomics, WuXi Advanced Therapies, Xyphos Biosciences, Yale Cancer Center, Yale University, Yeda Research and Development Company, Yposkesi, Ziopharm Oncology
Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.
The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.
Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• CRADA
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant
Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document
All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.
Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.
